Hot off the press in @NatureBiotech "The Sufficiency of Disclosure of Medical AI Patents with @WNicholsonPrice @CeBIL_Center @cambridgelaw. Full text at: or (1) To what extent are medical AI patents disclosed? How does this level

RT @TiMinCeBIL: So excited about our papers published this week:. #1 in @NatureMedicine: #Data Sharing in #Precision #Medicine: https://t.c….

RT @PeterSinger: Like some ethical guidelines for using LLMs like ChatGPT? My former student @JulianSavulescu and team provide a practical ….

RT @juliansavulescu: My team and I provide clear guidelines in NatureMachIntel to using LLMs ethically in research. A practical framework f….

Check out our just-published Nature Machine Intelligence @NatMachIntell "Guidelines for ethical use and acknowledgement of large language models in academic writing"

RT @TiMinCeBIL: Happy to see our 2 papers in new @JIPLP:. 1. The sufficiency of disclosure of #AI invention, with @mateo_aboy , @AparajitaL….

RT @AparajitaLath: Excited to share my article in JIPLP with @mateo_aboy, @TiMinCeBIL and K. Liddell on a hot-topic - Sufficiency of Disclo….

RT @EthicsPolicyLab: What is the impact of the EU's AI Act on AI- and ML-enabled medical devices? New paper out in @npjDigitalMed! 📣. @Effy….

RT @npjDigitalMed: The new EU AI Act introduces strict regulations for AI systems, notably impacting the #digitalhealth sector. This pers….

RT @TiMinCeBIL: Delighted to see our new paper on „Navigating the #EU #AI #Act: implications for regulated #digital #medical #products“ wit….

RT @TiMinCeBIL: 📣 Our new paper in @ScienceMagazine #Translational #Medicine with @johnliddicoat, A. Hamidzadeh, K. Liddell, M. Schito, @da….

RT @NatureBiotech: The sufficiency of disclosure of medical artificial intelligence patents

RT @classicaproject: 📣 Publication news! How can we balance privacy & accessibility in health data transfers post-Schrems II?. 📄 "Supplemen….

"[. ]manufacturers will continue using the 510(k) process independently of the degree of novelty incorporated into the new medical devices, given that it is still, on average, a faster path to market). An exception would be sophisticated applicants with valuable IP (e.g.,.

Under what conditions could a successful De Novo classification raise the barriers to entry for competitors’?.It is also possible for De Novo applicants to raise the barriers of entry for subsequent competitors. A De Novo applicant that has accumulated substantial.

Under what conditions could a successful De Novo classification facilitate competitors’ entry into the market? Answer at This question represents an important consideration when analyzing the impact of the De Novo regulatory pathway on competition in.

Other questions:.- Is the De Novo process being used (or used more frequently) as a regulatory pathway for SaMD (Software as a Medical Device)?.-Under what conditions could a successful De Novo.classification facilitate competitors’ entry into the market?.-Under what conditions.